SUBCUTANEOUS FORMULATION OF ANTI-HER2 ANTIBODY
Номер патента: PE20131324A1
Опубликовано: 04-11-2013
Автор(ы): Hanns-Christian Mahler, Michael Adler, Oliver Boris Stauch, Ulla Grauschopf
Принадлежит: Hoffmann La Roche
Опубликовано: 04-11-2013
Автор(ы): Hanns-Christian Mahler, Michael Adler, Oliver Boris Stauch, Ulla Grauschopf
Принадлежит: Hoffmann La Roche
Реферат: SE REFIERE A UNA FORMULACION FARMACEUTICA DE UN ANTICUERPO ANTI-HER2 ALTAMENTE CONCENTRADA Y ESTABLE, PARA ADMINISTRACION SUBCUTANEA Y QUE CONTIENE: A) ENTRE 50 Y 350 MG/ML DEL ANTICUERPO ANTI-HER2; B) ENTRE 1 Y 100 mM DE UN AGENTE TAMPONADOR QUE PROPORCIONA UN PH DE 5,5; C) ENTRE 1 Y 500 mM DE UN ESTABILIZANTE O UNA MEZCLA DE DOS O MAS ESTABILIZANTES; Y D) ENTRE 0,01 Y 0,1% DE UN TENSIOACTIVO NO IONICO. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE CANCER Y CARECE DE LA ENZIMA HIALURONIDASA IT REFERS TO A PHARMACEUTICAL FORMULATION OF A HIGHLY CONCENTRATED AND STABLE ANTI-HER2 ANTIBODY, FOR SUBCUTANEOUS ADMINISTRATION AND CONTAINING: A) BETWEEN 50 AND 350 MG / ML OF ANTI-HER2 ANTIBODY; B) BETWEEN 1 AND 100 mM OF A BUFFER AGENT THAT PROVIDES A PH OF 5.5; C) BETWEEN 1 AND 500 mM OF A STABILIZER OR A MIXTURE OF TWO OR MORE STABILIZERS; AND D) BETWEEN 0.01 AND 0.1% OF A NON-IONIC SURFACTANT. SUCH FORMULATION IS USEFUL IN THE TREATMENT OF CANCER AND LACKS THE ENZYME HYALURONIDASE
Subcutaneous anti-HER2 Antibody Formulations and Uses Thereof
Номер патента: US20240207400A1. Автор: Michael Adler,Oliver Boris Stauch,Hanns-Christian Mahler,Ulla Grauschopf. Владелец: Genentech Inc. Дата публикации: 2024-06-27.